Trending Now
BUSINESS
U.S. Food and Drug Administration Places Clinical Hold On Cellectis MELANI-01...
Cellectis a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELANI-01 trial has...
MEDICAL DEVICES
MANUFACTURING
Helix BioPharma Corp. announces the signing of a non-binding letter of...
Helix BioPharma Corp., a clinical stage immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced that it has signed a...
DON'T MISS
JOURNAL SPOTLIGHT
Stem cell biologist at Harvard retracts diabetes breakthrough manuscript published in...
A diabetes breakthrough manuscript published by Douglas A. Melton, PhD, Co-Director of Harvard Stem Cell Institute (Ref: Cell 153, 747–758; May 9, 2013)
In this article,...
EVEN MORE NEWS
